Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab combined with daratumumab and pomalidomide significantly prolongs progression-free survival in relapsed or refractory multiple myeloma, with 24-month estimates over 81%.

• Why it matters: Improving outcomes for heavily pretreated multiple myeloma patients remains a challenge, as current therapies often have limited efficacy and durability.
• What they did: A phase 3 trial randomly assigned 864 patients to receive either talquetamab plus daratumumab and pomalidomide (Tal-DP), talquetamab plus daratumumab (Tal-D), or daratumumab with pomalidomide and dexamethasone (DPd), assessing progression-free survival and response rates.
• The result: Both Tal-DP and Tal-D significantly outperformed DPd, with higher response rates, deeper remissions, and improved overall survival, supporting their potential as effective treatment options in this setting.